RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis

Background Systemic sclerosis (SSc) is a multiorgan autoimmune disorder characterized by sclerosis of the skin and organs as well as the presence of antinuclear autoantibodies. Several types of antinuclear autoantibodies have been described in SSc, associated with distinct disease entities and diffe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of dermatology 2016-08, Vol.55 (8), p.882-885
Hauptverfasser: Terras, Sarah, Hartenstein, Hans, Höxtermann, Stefan, Gambichler, Thilo, Kreuter, Alexander
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Systemic sclerosis (SSc) is a multiorgan autoimmune disorder characterized by sclerosis of the skin and organs as well as the presence of antinuclear autoantibodies. Several types of antinuclear autoantibodies have been described in SSc, associated with distinct disease entities and differences in prognosis. Methods The aim of this study was to screen for the presence of antibodies reacting with RNA polymerase III (anti‐RNAP3) in a large cohort of patients with SSc treated at a tertiary referral center and to evaluate correlations with disease severity. Results Anti‐RNAP3 antibodies were detected in 11 of 158 patients (7.0%). Eight of the 11 (72.7%) anti‐RNAP3‐positive patients had diffuse cutaneous SSc (P < 0.01). A higher modified Rodnan skin score, associated with diffuse SSc, correlated with the presence of anti‐RNAP3 (P < 0.0001). The detection of anti‐RNAP3 antibodies strongly correlated with the presence of renal involvement (P < 0.0001). The odds ratio of RNAP3‐positive patients to develop renal involvement was 80.1 (95% CI 9.3–690.1). Conclusions This study demonstrates that the detection of anti‐RNAP3 antibodies in patients with SSc correlates with renal crisis and severe cutaneous involvement. The possibility to detect specific antibodies with a prognostic value can lead to a better risk management of patients with SSc.
ISSN:0011-9059
1365-4632
DOI:10.1111/ijd.13032